Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib for Lung Cancer Chemoprevention
NCT00020878Phase 2Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Mar 2001
- Primary completion
- Nov 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of celecoxib oral solution in non-small cell lung cancer (NSCLC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoints: Expression of Cox-2 in the lungs at 1 year and Intrapulmonary formation of PGE2 at 1 year. Started Mar 2001; status: completed.
02
Drugs
celecoxib oral solution
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00020878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00020878.